UBS downgrades Carlyle as weak fund returns threaten 2028 growth targets
UBS downgraded Carlyle Group to Neutral, cutting its price target to $47 from $60. The firm cited weaker private equity fund performance and delayed fundraising, which may hinder Carlyle's 2028 targets. UBS forecasts fee-related earnings of $1.68B, below Carlyle's $1.9B goal. Fundraising delays and smaller, growing businesses also pose challenges.
How this was made
The 30-second read
Why it matters
The downgrade may trigger short‑selling and reduce inflows into Carlyle‑focused funds, while competitors like Apollo and TPG could attract reallocations.
Market read
Analyst downgrade with a sizable price‑target cut is a fresh catalyst that can move CG lower in the short term.
What to watch
Potential upside from emerging private‑credit products and a rebound in fundraising cycles later in 2027.
Background
UBS analysts lowered Carlyle's growth forecasts after observing sub‑mid‑teens IRR on its flagship funds and delayed capital deployment for upcoming vehicles.
Ticker impact
UBS downgraded Carlyle Group to Neutral and cut its 12‑month price target to $47, citing weaker fund performance and delayed fundraising.
downward pressure as investors price in slower growth and reduced fee‑related earnings.
Analyst downgrade with a 23% price‑target cut is a concrete catalyst that typically drives the stock lower.
Market effects
Private‑equity sector may see broader valuation pressure as peers reassess fundraising outlooks.
U.S. markets could see a modest dip in financials focused on alternative assets.
Limited to firms with exposure to private‑equity fee‑related earnings.
Counterpoint
Carlyle's diversification into wealth management, insurance, and private credit could mitigate near‑term earnings slowdown.
Key entities
- companyCarlyle Group
Global alternative‑asset manager (ticker CG).
- analystUBS
Investment bank providing the downgrade and new price target.

